Lofexidine, sold as Lucemyra, holds a specific distinction: it’s the only medication FDA-approved specifically for managing opioid withdrawal symptoms that isn’t itself an opioid.
How it works: Similar to clonidine, lofexidine reduces the autonomic nervous system rebound that drives many withdrawal symptoms (sweating, rapid heart rate, anxiety, muscle aches) — it’s in the same broad medication class as clonidine but was developed and specifically studied for this exact use.
Why the FDA approval matters: Because it went through clinical trials specifically for opioid withdrawal (rather than being used off-label like clonidine), there’s a more direct evidence base supporting its use for this specific purpose.
What it doesn’t do: Like clonidine, lofexidine manages specific withdrawal symptoms — it doesn’t address opioid cravings the way medication for opioid use disorder does, and it’s not a treatment for opioid use disorder itself, just a tool for getting through withdrawal more comfortably.
Cost consideration: Lofexidine has historically been significantly more expensive than generic clonidine for a comparable symptom-management effect — worth discussing with your provider whether the FDA-approval specificity is worth the cost difference for your situation, or whether clonidine is a reasonable alternative.
Side effects: Similar to clonidine — most notably low blood pressure and dizziness — monitored the same way.
Medically reviewed by [pending]. Source: FDA prescribing information for lofexidine/Lucemyra.